用于恶性肿瘤治疗的体内外 nk 细胞的质量控制

Cardiometry Pub Date : 2023-11-01 DOI:10.18137/cardiometry.2023.29.conf.16

M. Lukashina, M.D. Mollaev, A. Posvyatenko, A.V. Kibardin, M.A. Maschan, S. S. Larin

{"title":"用于恶性肿瘤治疗的体内外 nk 细胞的质量控制","authors":"M. Lukashina, M.D. Mollaev, A. Posvyatenko, A.V. Kibardin, M.A. Maschan, S. S. Larin","doi":"10.18137/cardiometry.2023.29.conf.16","DOIUrl":null,"url":null,"abstract":"The process of transferring the technology for obtaining a drug from the laboratory to production and, then, to the clinical practice is always a very complicated and time-consuming way, requiring many adaptation solutions. Regarding biomedical cell products (BMCP), this is even a more complex process, requiring large-scale expansion of procedures to obtain clinically significant numbers of cells, adaptation to reagents and equipment, and establishment of safety parameters for reagents, equipment and the final product. Nevertheless, cell therapy has become an integral part of treatment regimens for malignant neoplasms. Today, thousands of studies of BMCP are being conducted around the world, both in mono-regimen and in various regimen combinations.","PeriodicalId":41726,"journal":{"name":"Cardiometry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"QUALITY CONTROL OF NK CELLS PRODUCED EX VIVO FOR MALIGNANT NEOPLASM THERAPY\",\"authors\":\"M. Lukashina, M.D. Mollaev, A. Posvyatenko, A.V. Kibardin, M.A. Maschan, S. S. Larin\",\"doi\":\"10.18137/cardiometry.2023.29.conf.16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The process of transferring the technology for obtaining a drug from the laboratory to production and, then, to the clinical practice is always a very complicated and time-consuming way, requiring many adaptation solutions. Regarding biomedical cell products (BMCP), this is even a more complex process, requiring large-scale expansion of procedures to obtain clinically significant numbers of cells, adaptation to reagents and equipment, and establishment of safety parameters for reagents, equipment and the final product. Nevertheless, cell therapy has become an integral part of treatment regimens for malignant neoplasms. Today, thousands of studies of BMCP are being conducted around the world, both in mono-regimen and in various regimen combinations.\",\"PeriodicalId\":41726,\"journal\":{\"name\":\"Cardiometry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiometry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18137/cardiometry.2023.29.conf.16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiometry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18137/cardiometry.2023.29.conf.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

从实验室到生产，再到临床实践，获取药物的技术转移过程总是非常复杂和耗时，需要许多适应性解决方案。就生物医用细胞产品（BMCP）而言，这一过程甚至更为复杂，需要大规模扩展程序，以获得具有临床意义的细胞数量，对试剂和设备进行调整，并建立试剂、设备和最终产品的安全参数。尽管如此，细胞疗法已成为恶性肿瘤治疗方案中不可或缺的一部分。如今，世界各地正在进行数千项 BMCP 研究，既有单一疗法，也有各种疗法组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

QUALITY CONTROL OF NK CELLS PRODUCED EX VIVO FOR MALIGNANT NEOPLASM THERAPY

The process of transferring the technology for obtaining a drug from the laboratory to production and, then, to the clinical practice is always a very complicated and time-consuming way, requiring many adaptation solutions. Regarding biomedical cell products (BMCP), this is even a more complex process, requiring large-scale expansion of procedures to obtain clinically significant numbers of cells, adaptation to reagents and equipment, and establishment of safety parameters for reagents, equipment and the final product. Nevertheless, cell therapy has become an integral part of treatment regimens for malignant neoplasms. Today, thousands of studies of BMCP are being conducted around the world, both in mono-regimen and in various regimen combinations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cardiometry MEDICAL LABORATORY TECHNOLOGY-

自引率

0.00%

发文量

审稿时长

6 weeks

期刊介绍： Cardiometry is an open access biannual electronic journal founded in 2012. It refers to medicine, particularly to cardiology, as well as oncocardiology and allied science of biophysics and medical equipment engineering. We publish mainly high quality original articles, reports, case reports, reviews and lectures in the field of the theory of cardiovascular system functioning, principles of cardiometry, its diagnostic methods, cardiovascular system therapy from the aspect of cardiometry, system and particular approaches to maintaining health, engineering peculiarities in cardiometry developing. The interdisciplinary areas of the journal are: hemodynamics, biophysics, biochemistry, metrology. The target audience of our Journal covers healthcare providers including cardiologists and general practitioners, bioengineers, biophysics, medical equipment, especially cardiology diagnostics device, developers, educators, nurses, healthcare decision-makers, people with cardiovascular diseases, cardiology and engineering universities and schools, state and private clinics. Cardiometry is aimed to provide a wide forum for exchange of information and public discussion on above scientific issues for the mentioned experts.